AIRS Airsculpt Technologies, Inc.
Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1870940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.3%
TTM net income YoY47.7%
TTM EPS YoY60.0%
Revenue 3-yr CAGR-7.9%
Net income 3-yr CAGR—
Margins
Gross margin60.2%
Operating margin-4.7%
Net margin-6.4%
FCF margin-1.7%
EBITDA margin3.4%
Returns
ROE-10.1%
ROA-5.0%
ROIC (approx.)-4.2%
Asset turnover0.79x
Leverage & solvency
Liabilities / assets43.6%
Debt / equity0.35x
Current ratio0.85x
Interest coverage-1.40x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $31.94M | $42.90M | $39.39M | $33.44M | $34.99M | $44.01M | $39.37M | $39.18M |
| Cost of revenue | $12.91M | $16.57M | $15.59M | $13.68M | $14.86M | $17.20M | $15.95M | $16.75M |
| Gross profit | $19.03M | $26.33M | $23.80M | $19.77M | $20.13M | $26.81M | $23.42M | $22.43M |
| SG&A expense | $20.26M | $23.42M | $22.58M | $18.22M | $19.52M | $22.67M | $21.77M | $23.36M |
| Operating income | -$4.14M | -$29,000 | -$1.80M | -$1.01M | -$9.75M | $786,000 | -$1.59M | -$4.13M |
| Interest expense | $1.24M | $1.04M | $1.20M | $1.48M | $1.41M | $1.56M | $1.62M | $1.61M |
| Pretax income | -$5.38M | -$1.21M | -$2.86M | -$2.49M | -$11.16M | -$776,000 | -$3.21M | -$5.74M |
| Income tax | $1.79M | -$101,000 | -$465,000 | -$3.77M | -$1.65M | -$185,000 | -$367,000 | -$706,000 |
| Net income | -$7.17M | -$1.11M | -$2.40M | $1.28M | -$9.51M | -$591,000 | -$2.85M | -$5.03M |
| EBITDA | -$1.24M | $2.91M | $1.22M | $2.07M | -$6.53M | $4.03M | $1.65M | -$936,000 |
| EPS (basic) | -0.10 | -0.02 | -0.03 | — | -0.15 | -0.01 | -0.05 | — |
| EPS (diluted) | -0.10 | -0.02 | -0.03 | — | -0.15 | -0.01 | -0.05 | — |
| Weighted avg. shares (diluted) | 72.54M | 70.79M | 69.46M | — | 62.44M | 59.59M | 58.54M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $15.18M | $18.82M | $16.69M | $8.45M | $5.41M | $8.19M | $5.55M | $8.23M |
| Current assets | $23.05M | $27.50M | $24.33M | $15.46M | $12.22M | $16.41M | $15.30M | $17.12M |
| PP&E, net | $23.01M | $24.50M | $26.01M | $27.81M | $29.51M | $33.85M | $35.75M | $37.47M |
| Goodwill | $81.73M | $81.73M | $81.73M | $81.73M | $81.73M | $81.73M | $81.73M | $81.73M |
| Intangibles | $33.27M | $34.46M | $35.65M | $36.84M | $38.03M | $39.22M | $40.40M | $41.59M |
| Total assets | $187.78M | $193.28M | $192.00M | $187.30M | $185.92M | $198.37M | $203.26M | $212.78M |
| Current liabilities | $27.21M | $34.95M | $32.48M | $27.90M | $24.16M | $25.83M | $26.79M | $28.95M |
| Short-term debt | $5.46M | $10.46M | $5.46M | $5.46M | $5.00M | $4.55M | $4.25M | $4.25M |
| Long-term debt | $31.20M | $33.11M | $39.36M | $50.59M | $51.91M | $53.19M | $64.26M | $65.46M |
| Total debt | $36.66M | $43.57M | $44.82M | $56.05M | $56.91M | $57.74M | $68.51M | $69.71M |
| Total liabilities | $81.84M | $88.45M | $91.74M | $99.59M | $103.81M | $107.21M | $125.93M | $134.59M |
| Shareholders' equity | $105.94M | $104.83M | $100.26M | $87.71M | $81.00M | $90.06M | $76.23M | $78.19M |
| Net debt | $21.48M | $24.74M | $28.13M | $47.60M | $51.51M | $49.55M | $62.96M | $61.47M |
| Shares outstanding | 73.93M | 71.52M | 70.55M | 64.54M | 62.44M | 62.44M | 58.66M | 58.37M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.48M | -$1.24M | $5.27M | -$2.53M | -$225,000 | $4.98M | $868,000 | $2.71M |
| Capital expenditure | $226,000 | $228,000 | $51,000 | $58,000 | $180,000 | $265,000 | $1.90M | $3.53M |
| Free cash flow | -$3.70M | -$1.47M | $5.22M | -$2.59M | -$405,000 | $4.72M | -$1.03M | -$815,000 |
| Investing cash flow | -$226,000 | -$228,000 | -$51,000 | -$58,000 | -$180,000 | -$265,000 | -$1.90M | -$3.53M |
| Financing cash flow | $59,000 | $3.60M | $3.02M | $5.63M | -$2.38M | -$2.08M | -$1.65M | $3.08M |
| Depreciation & amortization | $2.90M | $2.94M | $3.02M | $3.08M | $3.22M | $3.25M | $3.24M | $3.19M |
| Stock-based compensation | $1.10M | $900,000 | $559,000 | -$1.39M | $1.10M | $1.40M | $1.24M | $2.24M |
| Dividends paid | — | — | — | $0 | $0 | $0 | $0 | $238,000 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.